Tumour Models London Summit on December 04-05, 2024 in London, United Kingdom

With 5% of cancer drugs going into the clinic, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery, particularly with such a high price tag for clinical failure.

The 13th Tumour Models London Summit stands as the only industry-led meeting uniting pharma, biotech, and preclinical CROs from Europe to network and discuss new trends and innovations in tumour models. Attracting leading preclinical and translational expertise, this forum provides an essential platform for scientists and decision makers to hear about the latest innovations in in vivo and in vitro tumour modelling to de-risk their studies and accelerate their product's journey from lab to patient.

URLs:

Tickets: https://go.evvnt.com/2609942-2?pid=10008

Brochure: https://go.evvnt.com/2609942-3?pid=10008

Prices:
Vendor Pricing - Conference Only: GBP 3099.00,
Drug Developers and Academics - FREE: GBP 0.00

Speakers: Fabien Garcon, Senior Scientist, AstraZeneca, Ilona-Petra Maser, Senior Scientist and Group Leader, iOmx Therapeutics, Joel Plumas, Co-Founder and Chief Scientific Officer, PDC*line Pharma, Loic Poiraudeau, Postdoctoral Fellow, Institute Gustave Roussy, Lucas Chaible, Senior Scientist, iTeos Therapeutics, Lucas Trucco, Principal Scientist, Oncology, Johnson and Johnson Innovative Medicine, Madelon Paauwe, Senior Scientist - Preclinical In Vivo Pharmacology, Genmab, Mads Daugaard, President and Chief Scientific Officer, Rakovina Therapeutics, Manon Simard, Postdoctoral Research, Translational Oncology, Merck, Mark Albertella, Senior Director – Oncology Biosciences, AstraZeneca, Martyna Popis, Scientist, Cell and Antibody Therapy, MiNK Therapeutics, Michaela Nahler, Head of Regulatory Affairs, Former Senior Director, Head Regulatory Affairs Europe, Urovant Sciences, Nicholas Glanville, Vice President Research, Prokarium, Paola Marco-Casanova, Director, Translational Medicine, Oncology R and D, AstraZeneca, Philip Huxley, Vice President – Oncology, Bicycle Therapeutics, Ravashnee Naidoo, Senior Scientist –Tumour Profiling, Translational Sciences Group, Adaptimmune Therapeutics, Shamin Li, In Vitro Pharmacology Team Leader, Servier, Somaieh Hedayat, Principal Scientist, Translational Models Lead, Econic Biosciences, Stefan Bissinger, Head of Preclinical Pharmacology and Biomarker Development, iOmx Therapeutics, Wesley Minto, Senior Associate Scientist, Preclinical Pathology Team Lead, Gilead Sciences

Time: 07:20 to 17:10